Tuesday, May 02, 2023 7:50:49 AM
In a previous post (540185), I came up w a scenario of what personnel would be needed for NWBO to stay independent after marketed drug approval by a Regulatory Agency. It wouldn't take many hires to launch the drug. Just a higher up person or so in Regulatory Affairs, QA, Manufacturing, Medical Affairs, Marketing, and Sales and w additional sales peeps coming on board near launch. I felt this was a very plausible scenario. Of course, after approval, NWBO would need to hire a slew of others such as in Clinical. After having this discussion the last time, I was curious what were the job functions of those 15 - 20 persons who worked at NWBO so I joined LinkedIn to try to find out. On initially joining, I was able to see there were about 16 people listed there and nothing stood out that would make me think they want to remain independent but I rationalized they are waiting till MAA/BLA submission to start the hiring process. I tried looking now, and I was unsuccessful in looking at the LinkedIn NWBO to see if they (not Advent) were hiring. I don't know if I was unsuccessful in searching because I only have free membership, or am not a business owner, or just don't know how to navigate the site but I'd be curious to know if NWBO, at this point in time, hired for any of the positions that would be needed to stay as an independent company. It doesn't seem to make sense to hire consultants to perform these functions because that would get really expensive, and I don't think you can have these positions at Advent because even though Advent and NWBO are joined at the hip they are two different entities and I believe there would be some conflict of interest if Advent, as the manufacturing CDMO, fully released drug to market. The correct way would be for Advent to release drug to the Sponsor and Sponsor release drug to market (i.e. no conflict of interest). So in sum, unless these minimal few positions are being hired at NWBO, I'd have to agree w you.
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
